17-OR: Efficacy and Safety of Chiglitazar, a Novel PPARα/γ/d Pan-Agonist, in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Superiority Trial (CMAP)Linong Ji, WEIPING JIA, Weihong Song et al.|Diabetes|2019Cited by 5
A randomized, multicenter controlled trial to compare the efficacy of recombinant human parathyroid hormone (1-34) with elcatonin in postmenopausal women with osteoporosis in China.Xiuzhen Zhang, Yuan Jia, Xiaohui Guo et al.|PubMed|2009Cited by 5
Diabetes prevalence and its comorbidities in people aged 50 years and above in Xi'an: a community-based surveyJie Ming, Qiu-he Ji, Shaoyong Xu et al.|Chin J Diabetes Mellitus|2018Cited by 1